valsartan dexcel 40
dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.
valsartan dexcel 80
dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.for treatment of hypertension.
valsartan dexcel 160
dexcel pharma technologies ltd - valsartan - film coated tablets - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.for treatment of hypertension.
valsartan teva 80 mg film-coated tablets
teva pharma b.v. - valsartan - film-coated tablet - 80 milligram(s) - angiotensin ii antagonists, plain; valsartan
valsartan teva 40 mg film-coated tablets
teva pharma b.v. - valsartan - film-coated tablet - 40 milligram(s) - angiotensin ii antagonists, plain; valsartan
valsartan teva 160 mg film-coated tablets
teva pharma b.v. - valsartan - film-coated tablet - 160 milligram(s) - angiotensin ii antagonists, plain; valsartan
valsartan actavis 40 mg film-coated tablets
actavis group ptc ehf - valsartan - film-coated tablet - 40 milligram(s) - angiotensin ii antagonists, plain; valsartan
valsartan / hydrochlorothiazide teva 160 mg/25 mg film-coated tablets
teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics
valsartan/hydrochlorothiazide teva 160 mg/12.5 mg film-coated tablets
teva pharma b.v. - valsartan; hydrochlorothiazide - film-coated tablet - 160 mg /12.5 milligram(s) - angiotensin ii antagonists and diuretics; valsartan and diuretics
valsartan rowa 40 mg film-coated tablets
rowa pharmaceuticals limited - valsartan - film-coated tablet - 40 milligram(s) - angiotensin ii antagonists, plain; valsartan